Mersana Therapeutics - MRSN Stock Forecast, Price & News

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Mersana Therapeutics Price Performance

Shares of MRSN Stock traded up $1.70 during mid-day trading on Tuesday, hitting $6.95. 237,559 shares of the stock traded hands, compared to its average volume of 966,957. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.28 and a current ratio of 4.28. The firm has a market cap of $674.08 million, a price-to-earnings ratio of -2.92 and a beta of 1.94. The company's 50-day simple moving average is $4.58 and its 200-day simple moving average is $4.22. Mersana Therapeutics has a twelve month low of $2.68 and a twelve month high of $14.80.

Mersana Therapeutics (NASDAQ:MRSN - Get Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.28). Mersana Therapeutics had a negative return on equity of 119.10% and a negative net margin of 8,826.73%. The company had revenue of $2.04 million during the quarter, compared to analyst estimates of $20.01 million. During the same period in the prior year, the firm earned ($0.50) EPS. As a group, equities research analysts expect that Mersana Therapeutics will post -2.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MRSN. Robert W. Baird raised their price objective on Mersana Therapeutics from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Tuesday. SVB Leerink boosted their target price on Mersana Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a report on Tuesday. Finally, HC Wainwright lowered their target price on Mersana Therapeutics from $24.00 to $19.00 in a report on Monday, May 9th.

Insider Activity

In related news, Director Andrew A. F. Hack purchased 211,268 shares of the business's stock in a transaction dated Wednesday, May 18th. The shares were bought at an average price of $3.35 per share, with a total value of $707,747.80. Following the purchase, the director now directly owns 8,087,400 shares in the company, valued at approximately $27,092,790. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Mersana Therapeutics news, Director Andrew A. F. Hack acquired 211,268 shares of Mersana Therapeutics stock in a transaction dated Wednesday, May 18th. The stock was bought at an average cost of $3.35 per share, for a total transaction of $707,747.80. Following the purchase, the director now directly owns 8,087,400 shares in the company, valued at approximately $27,092,790. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Andrew A. F. Hack acquired 14,760 shares of the business's stock in a transaction on Thursday, June 2nd. The shares were bought at an average price of $3.20 per share, with a total value of $47,232.00. Following the completion of the transaction, the director now directly owns 8,663,673 shares of the company's stock, valued at $27,723,753.60. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 647,833 shares of company stock worth $2,123,323. Company insiders own 4.40% of the company's stock.